Longitudinal performance of polycaprolactone-based scaffold plus recombinant human morphogenetic protein-2 (rhBMP-2) in large preclinical animal model : 6- versus 12 months by Yong, Mostyn R. et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Yong, Mostyn R., Savi, Flavia M., Woodruff, Maria A., Saifzadeh, Siamak,
Askin, Geoffrey N., Labrom, Robert D., Hutmacher, Dietmar, & Adam,
Clayton J.
(2014)
Longitudinal performance of polycaprolactone-based scaffold plus recom-
binant human morphogenetic protein-2 (rhBMP-2) in large preclinical ani-
mal model : 6- versus 12 months. In
Raso, James & Aubin, Carl-Eric (Eds.)
The 10th Meeting of the International Research Society of Spinal Deformi-
ties (IRSSD 2014), 29 June - 2 July 2014, Sapporo, Japan.
This file was downloaded from: http://eprints.qut.edu.au/79636/
c© Copyright 2015 Yong et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the
terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original
work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated.
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1186/1748-7161-10-S1-O58
 1 
LONGITUDINAL PERFORMANCE OF POLYCAPROLACTONE-BASED SCAFFOLD PLUS 
RECOMBINANT HUMAN MORPHOGENETIC PROTEIN-2 (rhBMP-2) IN LARGE PRECLINICAL 
ANIMAL MODEL: 6- VERSUS 12 MONTHS 
 
*Yong MR1,2, Savi FM 2, Woodruff MA2, Saifzadeh S2, Askin GN1,2, Labrom RD1,2, Hutmacher DW2, 
Adam CJ1,2 
 
1. QUT/Mater Paediatric Spine Research Group, Queensland University of Technology, Mater Misericordiae Health 
Services, Brisbane, QLD, Australia. 
 
2. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia. 
 
Introduction 
There is strong current interest in the use of biodegradable scaffolds in combination with bone 
growth factors as a valuable alternative to the current gold standard autograft in spinal fusion 
surgery Yong et al. (2013). Here we report on 6- vs 12- month data set evaluating the longitudinal 
performance of a CaP coated polycaprolactone (PCL)  scaffold loaded with recombinant human 
bone morphogenetic protein-2 (rhBMP-2)  as a bone graft substitute within a preclinical ovine 
thoracic spine. 
 
Methods 
Twelve sheep underwent a 3-level (T6/7, T8/9 and T10/11) discectomy with randomly allocated 
implantation of a different graft substitute at each of the three levels; (i) calcium phosphate (CaP) 
coated polycaprolactone based scaffold plus 0.54µg rhBMP-2, (ii) CaP coated PCL- based scaffold 
alone or (iii) autograft (mulched rib head). Fusion assessments were performed via high resolution 
clinical computed tomography and histological evaluation were undertaken at six (n=6) and twelve 
(n=6) months post-surgery using the Sucato grading system (Sucato et al. 2004). 
 
Results 
The computed tomography fusion grades of the 6- and 12- months in the rhBMP-2 plus PCL- 
based scaffold group were 1.9 and 2.1 respectively, in the autograft group 1.9 and 1.3 respectively, 
and in the scaffold alone group 0.9 and 1.17 respectively. There were no statistically significant 
differences in the fusion scores between 6- and 12- month for the rhBMP plus PCL- based scaffold 
or PCL – based scaffold alone group however there was a significant reduction in scores in the 
autograft group. These scores were seen to correlate with histological evaluations of the respective 
groups.  
 
Conclusions 
The results of this study demonstrate the efficacy of scaffold-based delivery of rhBMP-2 in 
promoting higher fusion grades at 6- and 12- months in comparison to the scaffold alone or 
autograft group within the same time frame. Fusion grades achieved at six months using 
PCL+rhBMP-2 are not significantly increased at twelve months post surgery. 
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